Editas Medicine
Editas Medicine raises $118M Follow-on Offering at $1.8B valuation
Quick Facts
Editas Medicine: Follow-on Offering Funding Round
Editas Medicine has successfully raised $118M in Follow-on Offering funding, reaching a valuation of $1.8B.
Company Overview
Genome editing medicines
Funding Details
The Follow-on Offering round was led by Polaris Partners, with participation from Flagship Pioneering, Third Rock Ventures, Google Ventures.
Company Information
- Headquarters: 11 Hurley Street, Cambridge, MA 02141
- Founded: 2013
- Employees: 300+
- Category: Biotech
Investment
Editas Medicine plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Polaris Partners: Verified investor in Follow-on Offering
- Flagship Pioneering: Verified investor in Follow-on Offering
- Third Rock Ventures: Verified investor in Follow-on Offering
- Google Ventures: Verified investor in Follow-on Offering
Key Investors
About the Author
Related Company Reports
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...